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Abstract
Herpesviruses are large DNA viruses that are highly abundant within their host populations.
Even in the presence of a healthy immune system, these viruses manage to cause lifelong
infections. This persistence is partially mediated by the virus entering latency, a phase of in-
fection characterized by limited viral protein expression. Moreover, herpesviruses have de-
voted a significant part of their coding capacity to immune evasion strategies. It is believed
that the close coexistence of herpesviruses and their hosts has resulted in the evolution of
viral proteins that specifically attack multiple arms of the host immune system. Cytotoxic T
lymphocytes (CTLs) play an important role in antiviral immunity. CTLs recognize their target
through viral peptides presented in the context of MHCmolecules at the cell surface. Every
herpesvirus studied to date encodes multiple immune evasion molecules that effectively in-
terfere with specific steps of the MHC class I antigen presentation pathway. The transporter
associated with antigen processing (TAP) plays a key role in the loading of viral peptides
onto MHC class I molecules. This is reflected by the numerous ways herpesviruses have
developed to block TAP function. In this review, we describe the characteristics and mecha-
nisms of action of all known virus-encoded TAP inhibitors. Orthologs of these proteins en-
coded by related viruses are identified, and the conservation of TAP inhibition is discussed.
A phylogenetic analysis of members of the family Herpesviridae is included to study the ori-
gin of these molecules. In addition, we discuss the characteristics of the first TAP inhibitor
identified outside the herpesvirus family, namely, in cowpox virus. The strategies of TAP in-
hibition employed by viruses are very distinct and are likely to have been acquired indepen-
dently during evolution. These findings and the recent discovery of a non-herpesvirus TAP
inhibitor represent a striking example of functional convergent evolution.
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Introduction
The family Herpesviridae emerged approximately 400 million years ago [1]. The first members
of the class Mammalia arose 200 million years ago, at around the time of the Early Jurassic pe-
riod, and, since then, herpesviruses and mammals have coevolved and adapted to one another
over very long periods of time. Today, members of the family Herpesviridae are numerous and
widespread among not only mammals, but also many bird and reptile species; each virus dis-
plays a remarkable degree of host specificity. The longstanding interactions between virus and
host have likely contributed to the development of the host’s innate and adaptive immune sys-
tem and the mechanisms that viruses use to evade those systems.
The first line of defense against intruding pathogens is the innate immune system. This
comprises the complement system, natural killer (NK) cells, apoptosis, pattern recognition re-
ceptor-mediated intracellular signaling leading to the production of IFNβ and many other cy-
tokines and chemokines, and phagocytes like neutrophils, macrophages and dendritic cells.
Together, these mechanisms enable the host to limit replication and spread of a pathogen and
facilitate the induction of specific adaptive immune responses. The adaptive immune system
includes antibody-producing B-cells, CD4+ T-cells that recognize antigens presented in the
context of MHC (class) II molecules, and CD8+ T-cells that generally recognize antigens in the
context of MHC I molecules.
During and following protein synthesis, a proportion of the resulting proteins is rapidly de-
graded into peptides by the proteasome. The resulting peptides are subsequently translocated
into the lumen of the endoplasmic reticulum (ER) via the transporter associated with antigen
processing (TAP) [2,3]. Within the ER, the peptides are loaded onto newly synthesized MHC I
heavy chain / β2microglobulin (β2m) heterodimers. This process is facilitated by at least five
ER-resident molecules that together form the MHC I peptide-loading complex (PLC). Tapasin
functions as a chaperone, bridging MHC I molecules and TAP and catalyzing the binding of
high-affinity peptides [4–10]. The lectin-like chaperones calnexin and calreticulin promote
folding of newly synthesized MHC I molecules; additionally, calreticulin recruits the thioloxi-
doreductase ERp57. ERp57 and protein disulfide isomerase (PDI) are involved in stabilizing
several protein-protein interactions within the PLC via disulfide bond formation [11,12]. Ac-
quisition of peptide allows mature MHC I complexes to leave the ER, pass through the Golgi,
and traffic to the cell surface where the peptides are presented to CTLs.
The family Herpesviridae is divided into the subfamilies Alphaherpesvirinae, Betaherpesviri-
nae, and Gammaherpesvirinae. Members of this family have been identified in many different
species, including reptiles, birds, and mammals. There are nine herpesviruses known to infect
humans: herpes simplex virus (HSV) types 1 and 2 (HSV-1 and HSV-2 in speciesHuman herpes-
virus 1 andHuman herpesvirus 2, respectively, of genus Simplexvirus, subfamily Alphaherpesviri-
nae), varicella-zoster virus (VZV in speciesHuman herpesvirus 3 of genus Varicellovirus,
subfamily Alphaherpesvirinae), human cytomegalovirus (HCMV in speciesHuman herpesvirus
5 of genus Cytomegalovirus, subfamily Betaherpesvirinae), human herpesviruses 6A, 6B and 7
(HHV-6A, HHV-6B, HHV-7 in speciesHuman herpesvirus 6A,Human herpesvirus 6B and
Human herpesvirus 7 of genus Roseolovirus, subfamily Betaherpesvirinae), Epstein-Barr virus
(EBV in speciesHuman herpesvirus 4 of genus Lymphocryptovirus, subfamily Gammaherpesviri-
nae) and Kaposi’s sarcoma-associated herpesvirus (KSHV in speciesHuman herpesvirus 8 of
genus Rhadinovirus, subfamily Gammaherpesvirinae) [13]. Most of these viruses are widespread
within the human population; for example, in the United States, approximately 90% of individu-
als of 80 years or older are seropositive for HCMV [14]. VZV is even more abundant, with a se-
roprevalence of 95% in people from 20 years of age [15]. Herpesvirus infections generally cause
only mild symptoms, but in some circumstances they exhibit significant pathogenic properties,
PLOS Pathogens | DOI:10.1371/journal.ppat.1004743 April 16, 2015 2 / 19
with the most serious complications tending to arise in immunocompromised people. Thus,
HSV-1 can cause encephalitis, EBV and KSHV are associated with malignancies, and HCMV in-
fection can result in congenital defects [16–18].
Following primary infection of their host, herpesviruses establish a state of latency in which
viral protein expression is limited. As a consequence of this strategy, the virus-derived pool of
potential antigens is minimized, thus hindering recognition and elimination of infected cells by
CTLs and enabling the virus to persist for the lifetime of the host. In addition, several latency-
associated proteins have been found actively to impede detection of virus-infected cells by the
host immune system [19–21]. However, at some point, in order to disseminate the virus to
other hosts, productive infection must occur. During this replicative or lytic phase, an extensive
repertoire of herpesvirus-encoded genes is expressed in a kinetically regulated fashion. De-
pending on the virus in question, this results in the synthesis of at least 70 functional proteins,
and renders the virus-infected cell susceptible to the memory immune responses that were gen-
erated during primary infection. Although these responses are instrumental in controlling in-
fection and in limiting pathology, herpesviruses employ multiple evasion strategies to allow
virus production in the face of existing antiviral immunity, thereby promoting spread within
the host population.
In the past two decades, numerous articles have been published identifying and characteriz-
ing the immune evasion molecules expressed by herpesviruses. Most of these publications are
focused on human herpesviruses, each of which has been shown to employ several strategies to
interfere with the innate and adaptive immune responses. The MHC I presentation pathway
appears to be a favorite target among the herpesviruses, illustrating the importance of CTLs in
the elimination of virus-infected cells. Every step of this pathway is targeted by at least one her-
pesvirus. The availability of MHC I is affected by so-called host shutoff proteins that block cel-
lular protein synthesis and thus expression of newly synthesized MHC I molecules. Examples
of these proteins are the HSV-1-encoded vhs or UL41, EBV BGLF5, and KSHV SOX or ORF37
[22–26]. Additional strategies focus on inducing the degradation of MHC I molecules, as medi-
ated by HCMV US2, US10, and US11 [27–29], murine CMV (MCMV) glycoprotein (gp) 48
[30], and murine gammaherpesvirus 68 mK3 [31–33]. Presentation of antigenic peptides by
MHC I is also affected by HCMV US3 and MCMV gp40, which cause the retention of imma-
ture molecules in the cis-Golgi [34,35]. Finally, EBV BILF1 and KSHV K3 and KSHV K5 en-
hance the endocytosis of MHC I complexes at the cell surface [36–39].
In addition to strategies that limit the availability of MHC I, many herpesviruses affect pep-
tide presentation by inhibiting the function of TAP. TAP is a heterodimeric ATP-binding cas-
sette (ABC) transporter complex composed of two subunits, TAP1 and TAP2 (Fig 1). Both
subunits are composed of an N-terminal transmembrane domain (TMD) and a C-terminal nu-
cleotide-binding domain (NBD) exposed in the cytosol (Fig 1). The TMDs of TAP1 and TAP2
contain 10 and 9 transmembrane (TM) helices, respectively. The N-terminal 4 TM helices of
TAP1 and the N-terminal 3 TM helices TAP2, known as TMD0s, act as autonomous interac-
tion platforms for tapasin [40]. Together with the NBDs, the C-terminal 6 membrane helices of
each TAP subunit form the core of the transporter. Expression of this core region is necessary
and sufficient for peptide transport [41].
TAP preferentially transports peptides of 8–16 amino acid residues in length, but can ac-
commodate peptides as large as 40 amino acid residues, albeit with lower efficiency [42–46].
The exact location of the peptide-binding pocket remains unclear, but cross-linking peptide
substrates to TAP and mutagenesis of TAP have shown that elements within the cytosolic ex-
tensions between the TM helices of both TAP1 and TAP2 are involved in peptide binding to
TAP [47,48]. These findings are further supported by homology modeling of TAP based on the
resolved crystal structures of other ABC transporters [49]. Three cytosolic pockets formed by
PLOS Pathogens | DOI:10.1371/journal.ppat.1004743 April 16, 2015 3 / 19
PLOS Pathogens | DOI:10.1371/journal.ppat.1004743 April 16, 2015 4 / 19
TM helices of the TAP core complex have been proposed to represent the binding site for the
peptide substrates [49].
TAP-mediated peptide transport is energized by ATP hydrolysis at the NBDs, which harbor
two functionally nonequivalent ATP-binding sites. These sites are composed of conserved do-
mains within both subunits, including the Walker A and B domains of one NBD and a signa-
ture motif of the opposing NBD. The consensus ATP-binding site that includes the Walker A
and B domains of TAP2 has catalytic amino acid residues conserved among ABC transporters.
The degenerate ATP-binding site, which includes the Walker A and B domains of TAP1, has a
number of noncanonical mutations that reduce its catalytic activity [50]. Although ATP bind-
ing and hydrolysis can still occur at the degenerate site [51,52] only ATP binding and hydroly-
sis at the consensus TAP2 site is essential for completion of the transport cycle [50,52–54].
The crystal structures of several ABC transporters, trapped in distinct conformations, have
been resolved [55–59]. These structures, together with biochemical studies on TAP itself, sug-
gest that TAP transport occurs in sequential steps with extensive conformational rearrange-
ments of the NBDs and TMDs, which depend on nucleotide and peptide substrate binding
[60,61] (reviewed by [62]). In an inward-facing conformation, the peptide-binding pocket
faces the cytosol and the NBDs are separated. At this stage, TAP is receptive to both peptide
and ATP. The binding of peptide and ATP can occur independently and induces conforma-
tional rearrangements that partially close the NBDs. The NBDs are only fully closed when both
peptide and ATP are bound. These conformational changes are relayed to the TMDs and result
in an outward-facing conformation of TAP, thereby exposing the peptide-binding pocket into
the ER lumen and allowing release of the peptide. Upon ATP hydrolysis, the NBDs dissociate
and the TMDs rotate back into an inward-facing conformation [62]. In this way, conforma-
tional changes driven by peptide binding, ADP/ATP exchange, and ATP hydrolysis at the TAP
subunits lead to the transport of peptides into the ER lumen.
Cells that naturally or experimentally lack expression of functional TAP complexes show a
dramatic reduction in MHC I levels at their surface and a substantial decline in CTL sensitivity
[63–68]. Herpesviruses appear to have taken advantage of this extensive dependency of MHC I
expression on TAP function by encoding viral proteins that specifically impair TAP-mediated
peptide transport. This review focuses on the characteristics and evolution of herpesvirus-en-
coded TAP inhibitors and their orthologs.
Simplexvirus ICP47 Orthologs
The first viral protein found to inhibit TAP function was HSV-1 ICP47 (Fig 1). This protein acts
as a competitor of cytosolic peptides for TAP binding, thereby limiting the availability of peptides
in the ER lumen and causing subsequent retention of MHC I molecules in the ER [69–72].
ICP47 is expressed as a soluble, cytosolic protein of 88 amino acid residues. Mutational analyses
Fig 1. Interactions between herpesvirus-encoded TAP-inhibitors and their target.Upper illustration: model of the TAP transporter, comprising the two
subunits TAP1 and TAP2. Each subunit contains a transmembrane domain (TMD), encompassing 10 and 9 transmembrane (TM) helices for TAP1 and
TAP2, respectively. The outer N-terminal helices of TAP1 and TAP2 (TMD0) form an autonomous binding platform for tapasin, whereas the core 6 TM
helices are necessary for peptide transport. A peptide-binding domain is located within the cytosolic extensions of the TM helices. In addition, TAP1 and
TAP2 contain a nucleotide-binding domain (NBD) in the cytosol, which harbors two ATP-binding sites. Lower illustrations: schematic representations of the
interaction between the viral proteins and TAP. The sites where TAP is affected are indicated. HSV-1 ICP47 prevents peptide transport by physically
obstructing the peptide-binding site. PRV, BoHV-1 and EHV (EHV-1 and EHV-4) UL49.5 leave the transporter in a transformation-incompetent conformation,
thereby preventing the structural changes that are needed to translocate peptides over the ERmembrane. BoHV-1 UL49.5 is known to interact with a region
within the core domain of TAP, comprising the C-terminal 6 TM domains of both TAP1 and TAP2 [132]. BoHV-1 UL49.5 induces the degradation of both TAP
subunits, and EHV UL49.5 prevents ATP binding to TAP. HCMVUS6 blocks TAP by inducing conformational changes that result in diminished ATP binding
to TAP1. The protein interacts with TM domains 7–10 of TAP 1 and TM 1–4 of TAP2 [95]. EBV BNLF2a inhibits peptide transport by interfering with both
peptide and ATP binding to TAP.
doi:10.1371/journal.ppat.1004743.g001
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have defined residues 3–34 as the functional domain responsible for TAP binding and inhibition
of TAP function [73–75]. Charged residues within this domain are crucial for TAP inhibition,
and might mimic the N- and C-termini of peptide substrates within the peptide-binding pockets
of TAP [75]. Once bound to TAP, the viral protein traps TAP in a conformation that differs
from that of TAP in a peptide-bound state [76]. In contrast to peptide substrates, ICP47 blocks
ATP hydrolysis at the NBDs of TAP, which is normally followed by peptide binding, suggesting
that TAP is locked in an inward-facing conformation [51,77].
Orthologs of HSV-1 ICP47 are encoded by HSV-2 and other simplexviruses infecting Old
World primates, including herpesvirus papio 2 (HVP-2 in species Papiine herpesvirus 2) for ba-
boons, simian B virus (SBV in speciesMacacine herpesvirus 1) for macaques, and simian agent 8
(SA8 in species Cercopithecine herpesvirus 2) for African green monkeys [78]. Inhibition of TAP
is conserved for HSV-2 ICP47, despite the relatively low amino acid sequence identity (44%)
(Fig 2A) [79]. The ICP47 orthologs can be divided into two groups on the basis of sequence
similarities within the domain responsible for TAP inhibition, i.e., amino acid residues 3 to 34
[73–75]. HSV-1 and HSV-2 ICP47 are in the first group and share identity within this domain,
and both are known to inhibit TAP (Fig 2A) [79]. HPV-2, SBV, and SA8 ICP47 are in the second
group. The sequences of the N-terminal domain of these proteins show substantial identity to
each other and differ substantially from those of HSV-1 and HSV-2 (Fig 2A). SBV-infected cells
were shown to display minor MHC I downregulation compared to HSV-1-infected cells [80],
suggesting that the ICP47 protein encoded by SBV does not inhibit TAP. Given the similarities
between the SBV, HPV-2, and SA8 ICP47 proteins, the HPV-2 and SA8 ICP47 proteins may
also be unable to inhibit TAP, but data are not available. Thus, TAP inhibition may not be con-
served for all ICP47 proteins. The fact that ICP47 is only encoded by simplexviruses suggests
that this gene evolved after this lineage separated from the varicelloviruses (Fig 3). There is evi-
dence supporting the view that the ICP47 gene arose de novo, rather than being captured from
elsewhere, as is the case for many immune modulatory genes in herpesviruses [81].
Varicellovirus UL49.5 Orthologs
The second TAP inhibitor discovered within the subfamily Alphaherpesvirinae is the varicello-
virus UL49.5 protein. The most extensively studied member is bovine herpesvirus 1 (BoHV-1)
UL49.5. Unlike ICP47, UL49.5 does not affect the binding of peptides to TAP. Instead, the viral
protein binds to the core region of TAP and impairs TAP-mediated peptide transport through
two unique mechanisms. First, BoHV-1 UL49.5 inhibits the conformational rearrangements
that usually follow peptide and ATP binding, as inferred from fluorescence recovery after
photo bleaching (FRAP) assays [82]. Using this assay, the lateral mobility of Green Fluorescent
Protein (GFP)-tagged TAP can be measured in the ER-membrane. TAP mobility is affected by
the conformational rearrangements that occur upon peptide transport. Upon active peptide
transport, the mobility of TAP molecules is slower than that of inactive TAP [2]. In the pres-
ence of UL49.5, these changes in lateral mobility of TAP, and thus conformational rearrange-
ments, are halted [82]. Second, BoHV-1 UL49.5 strongly reduces TAP1 and TAP2 protein
levels by targeting both TAP subunits for proteasomal degradation (Fig 1) [82]. Mutational
analysis of BoHV-1 UL49.5 has attributed degradation of TAP to the first five N-terminal
amino acid residues and the ultimate residues of the C-terminal cytosolic domain of the protein
[83]. Interestingly, UL49.5 without a C-terminal domain does not cause degradation of TAP,
but retains the ability to inhibit peptide transport; this implies that the regions responsible for
this effect are located in the transmembrane or ER-luminal parts of the inhibitor [82].
Orthologs of UL49.5, also known as glycoprotein N (gN), are present in all members of the
family Herpesviridae sequenced to date. However, TAP inhibition by this protein has been
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found only among the varicelloviruses. The UL49.5 orthologs encoded by the varicelloviruses
BoHV-5, bubaline herpesvirus 1 (BuHV-1), cervid herpesvirus 1 (CvHV-1), equid herpesvirus
1 (EHV-1), EHV-4, pseudorabies virus (PRV), and felid herpesvirus 1 (FeHV-1) possess the
Fig 2. Alignments of the amino acid sequences of selected herpesvirus-encoded TAP-inhibitors. A) simplexvirus ICP47 orthologs, B) simplexvirus
(upper 5 lines) and varicellovirus (lower 12 lines) UL49.5 orthologs, C) cytomegalovirus US6 orthologs, and D) lymphocryptovirus BNLF2a orthologs. The
alignments of predicted primary translation products were made using ClustalW, followed by manual adjustment. The number of residues in each sequence
is shown on the right. Green highlights residues that are conserved in all sequences, and yellow highlights residues that are conserved in a majority. Bold N
residues in US6 indicate potential N-linked glycosylation sites. An illustrationof sequence disposition is shown below each alignment, with approximate
boundaries displayed.
doi:10.1371/journal.ppat.1004743.g002
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same functional properties as BoHV-1 UL49.5, causing a robust inhibition of peptide transport,
thereby decreasing MHC I molecules at the cell surface [84,85]. Infections with UL49.5-deletion
mutants of BoHV-1, EHV-1, and PRV have shown that UL49.5 is necessary and sufficient for
Fig 3. Phylogenetic tree for selectedmembers of the family Herpesviridae. The Bayesian tree is based on amino acid sequence alignments for six
large, well-conserved genes, namely the orthologs of HSV-1 genes UL15, UL19, UL27, UL28, UL29, and UL30, and is derived fromMcGeoch and Davison
[81]. Assignments to genera and subfamilies are shown on the right. Abbreviations not mentioned in the text are: MDV-1, Marek's disease virus type 1; MDV-
2, Marek's disease virus type 2; HVT, herpesvirus of turkey; ILTV, infectious laryngotracheitis virus; PsHV-1, psitticid herpesvirus 1; GTHV, green turtle
herpesvirus; THV, tupaia herpesvirus; GPCMV, guinea pig cytomegalovirus; CalHV-3, callitrichine herpesvirus 3; AHV-1, alcelaphine herpesvirus 1; OHV-2,
ovine herpesvirus 2; PLHV-1, porcine lymphotropic herpesvirus 1; HVS, herpesvirus saimiri; HVA, herpesvirus ateles; and RRV, rhesus rhadinovirus. Red,
blue, orange, and green shading indicate viruses that encode the ICP47, UL49.5, US6, or BNLF2a TAP inhibitor genes, respectively, and corresponding
coloring of virus abbreviations indicate viruses in which these genes have been shown to be functional TAP inhibitors. Light orange shading identifies all
members of the Cytomegalovirus genus that have a US6 gene. Light blue shading indicates all members of the herpesvirus family that code for a UL49.5
gene that might be involved in chaperoning maturation of glycoprotein M.
doi:10.1371/journal.ppat.1004743.g003
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TAP inhibition during viral infection in vitro [84]. Surprisingly, UL49.5 expressed by the varicel-
loviruses VZV, simian varicella virus (SVV), and canid herpesvirus 1 (CaHV-1) are incapable of
reducing TAP function [85]. Thus, the capacity to interfere with peptide transport via TAP is a
feature shared by a subgroup of varicellovirus-encoded UL49.5 orthologs.
The TAP-inhibiting UL49.5 homologs were shown to block human TAP as well as their nat-
ural host TAPs, indicating that the proteins target a highly conserved region within the TAP
complex [84,85]. Each UL49.5 ortholog appears to utilize a distinct mechanism of TAP inhibi-
tion. The capacity to arrest the TAP complex in a translocation incompetent state is conserved
for EHV-1 and PRV UL49.5 (Fig 1) [84] and most likely for EHV-4, BoHV-5, BuHV-1,
CvHV-1, and FeHV-1 UL49.5 [85]. The EHV-1 and EHV-4 UL49.5 proteins were shown to in-
terfere uniquely with ATP binding to TAP (Fig 1) [84]. UL49.5-induced degradation of TAP1
and TAP2 is conserved for the highly related viruses BoHV-1, BoHV-5, BuHV-1, and CvHV-
1, all of which infect ruminants, but not for EHV-1, EHV-4, PRV, and FeHV-1 UL49.5 (Fig 1)
[85]. The UL49.5 proteins interfering with TAP function show around 40% sequence identity
(Fig 2B). Proteasomal degradation of the transporter is only induced by the ruminant-infecting
viruses. The cytoplasmic domain of the TAP-degrading UL49.5 proteins contains two unique,
consecutive lysine residues and an RGRG motif (Fig 2B). These lysine residues, although po-
tential targets for ubiquitination, are not required for degradation of TAP [83]. However, the
arginine residues of the RGRG sequence appeared to be essential for this phenotype [83].
Based on current knowledge, the UL49.5 molecules are the only herpesvirus-encoded TAP
inhibitors that fulfill a dual role in viral infection. Within the infected cell, UL49.5 forms a het-
erodimeric complex with glycoprotein M (gM) and guides proper glycosylation and matura-
tion of this protein [86–88]. Cells expressing both BoHV-1 UL49.5 and gM show reduced TAP
inhibition when compared to cells expressing UL49.5 only, suggesting that the interaction be-
tween UL49.5 and gM interferes with the capacity of UL49.5 to block TAP [89]. However,
UL49.5 and gM display differential temporal expression in the context of viral infection, with
the appearance of UL49.5 preceding that of the late protein gM [89]. This provides UL49.5
with an opportunity to exert its immune evasive effect early during infection. Conservation of
both UL49.5 and gM in the family Herpesviridae indicates that the original role of UL49.5 was
that of a gM chaperone, and that TAP inhibition by the protein evolved later within the varicel-
lovirus subfamily, possibly in the BoHV-1 lineage after its divergence from the VZV lineage
(Fig 3). Alternatively, it is possible that the TAP inhibitory function was gained somewhat ear-
lier among the alphaherpesviruses, and lost in the VZV lineage, as VZV UL49.5 is capable of
interacting with the TAP complex even though it does not inhibit its activity.
Cytomegalovirus US6 Orthologs
HCMV encodes multiple immunoevasive proteins targeting the MHC I antigen presentation
pathway, including the TAP inhibitor US6 [90–92]. This protein impairs TAP function by in-
terfering with ATP binding to the transporter (Fig 1). US6 specifically prevents ATP binding to
TAP1, but stimulates ATP binding to TAP2 [93]. This is in contrast with the normal pattern of
ATP binding, which preferentially involves TAP1 [94]. US6 alters ATP binding to TAP by in-
ducing conformational rearrangements that are suggested to resemble TAP in an outward-fac-
ing conformation [77,95]. Rather than physically obstructing the ATP-binding site in the
cytosol, US6 induces these rearrangements by interacting with the ER luminal loops of TAP1
and TAP2 [95]. This observation is supported by data obtained with US6 truncation mutants,
which shows that the ER luminal domain of US6 is necessary and sufficient for the inhibition
of TAP [90,93].
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Orthologs of US6 are only encoded by cytomegaloviruses infecting primates [96]. The rhe-
sus CMV (RhCMV) ortholog of US6 (Rh185) shares only about 23% amino acid identity but
nevertheless reduces cell surface expression of MHC I molecules via TAP inhibition (Fig 2C).
The ER-luminal domain, identified as the functional part of US6 [90,93], shows remarkably
low identity between the two orthologs (Fig 2C). HCMV US6 is a member of the US6 gene
family, which is presumed to have arisen through gene duplication of a captured gene. The
original gene gave rise to a block of six contiguous paralogs (US6, US7, US8, US9, US10, and
US11), all encoding loosely related type I membrane proteins. Both the number of genes in this
family and their encoded sequences have diverged extensively among the primate cytomegalo-
viruses. For example, chimpanzee cytomegalovirus (CCMV) and HCMV both encode six ho-
mologous genes in the US6 family. In contrast, RhCMV and simian CMV (SCMV) each have
five genes, with orthology to HCMV being more difficult to determine [97]. Owl monkey cyto-
megalovirus (AoCMV) and squirrel monkey cytomegalovirus (SaCMV), which infect New
World primates, have four and seven members of the US6 family, respectively. However, these
are located in noncontiguous regions of the genome, and both viruses lack an obvious US6
ortholog. No US6 family genes are apparent in cytomegaloviruses of non-primate hosts, in-
cluding MCMV and rat CMV (RCMV) [96]. Thus, it seems that the US6 gene family probably
evolved during early primate evolution, with the TAP-inhibiting function arising in the Old
World primate lineage (Fig 3).
Lymphocryptovirus BNLF2a Orthologs
The gammaherpesvirus EBV codes for a lytically expressed TAP inhibitor, BNLF2a, that inhib-
its TAP by interfering with the binding of peptides and ATP to the transporter (Fig 1) [98,99].
Mechanistically, BNLF2a is thought to induce conformational changes in the TAP complex
that prevent association of ATP and peptide, but the sequence of events preceding the block in
TAP function remains to be elucidated. BNLF2a consists of a hydrophilic N-terminal domain
and a hydrophobic C-terminal domain (Fig 2D). BNLF2a lacks an obvious N-terminal signal
sequence but is membrane-integrated, nevertheless. The protein was identified as a tail-an-
chored transmembrane protein that uses Asna1/TRC40, among other proteins, for ER mem-
brane insertion [100]. This mechanism of localizing to membranes is unique among the
known viral TAP inhibitors.
Orthologs of BNLF2a have only been identified in lymphocryptoviruses that infect Old
World primates [98]. The BNLF2a orthologs encoded by rhesus, chimpanzee, baboon, and go-
rilla lymphocryptoviruses (RLV, CLV, BLV, and GoLV) share 53%–62% sequence identity
with EBV BNLF2a and display a similar disposition of hydrophilic and hydrophobic regions
(Fig 2D). When expressed in isolation, these orthologs downregulate cell surface expression of
MHC I molecules, indicating conserved TAP-inhibiting properties for BNLF2a proteins ex-
pressed by lymphocryptoviruses of Old World primates [98]. No orthologs of BNLF2a have
been detected in members of the genus Lymphocryptovirus that infect NewWorld primates,
suggesting that the BNLF2a gene was acquired after the divergence of Old World and New
World primate lymphocryptoviruses (Fig 3).
Conclusions
Members of all three subfamilies in the family Herpesviridae appear to exploit inhibition of
TAP-mediated peptide transport as an immune evasion strategy. The TAP inhibitors that have
been identified so far exhibit substantial variation in structural characteristics as well as in
mechanisms of action. Yet, despite their large diversity, all inhibitors have evolved to serve a
common end: diminish the supply of viral antigenic peptides into the ER lumen in order to
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avoid elimination of virus-infected cells by MHC I-restricted CTLs, thus ultimately aiding
virus replication and spread. The manner in which this has been achieved represents a striking
example of functional convergent evolution, and identifies TAP as an Achilles’ heel of the
immune system.
All of the TAP-inhibiting proteins described in this review are expressed early during the
viral replication cycle [89,91,99,101,102]. For example, EBV BNLF2a is expressed during the
(immediate-) early phase of lytic replication, but the protein levels are reduced at later times in
infection when other EBV-encoded immune evasive molecules are effective [103,104]. Similar-
ly, BoHV-1 UL49.5 is expressed with early kinetics, but remains present during the late stage of
infection [89]. This prolonged expression can be explained by the dual role that UL49.5 plays
during viral replication: early in infection, in the absence of gM, it acts as a TAP inhibitor,
while at later times of infection it also functions as a chaperone for the late, structural protein
gM that facilitates cell-to-cell spread of virus [89]. The early expression of herpesvirus-encoded
TAP inhibitors ensures inhibition of the transport of viral peptides into the ER for MHC asso-
ciation shortly after initiation of virus replication, before abundant viral protein synthesis
starts. In support of this reasoning, T cell recognition of antigenic peptides expressed early
after EBV reactivation is restored in cells infected with a BNLF2a-deleted recombinant EBV
[103]. These findings further substantiate the contribution of the virus-encoded TAP inhibitors
to immune evasion during infection.
Directly addressing the in vivo relevance of TAP inhibition for human herpesviruses is diffi-
cult, because of the restricted host specificity of these viruses. HSV is an exception to the rule,
as this virus can productively infect mice. The functional relevance of ICP47 was addressed
using a murine ocular infection model. Mice that received uniocular corneal infections with
wild-type HSV-1 developed encephalitis and died within 12 days [105]. However, mice infected
with an ICP47 deletion mutant did not develop encephalitis, pointing towards a role for ICP47
in preventing the activation of CD8+ T cells that avert the development of lethal encephalitis
[105]. An additional study showed that in systemically infected mice, an ICP47 deletion mu-
tant was also attenuated compared to wild type HSV-1. However, in mice lacking TAP, this
phenotype was reverted in neuronal tissues, including the brain, suggesting that TAP inhibition
is crucial for neuronal infection by HSV-1 [106]. The role of ICP47 in these mouse models
seems contradictory to studies showing that ICP47 fails to inhibit TAP efficiently in mouse cell
lines [69,70,79,107,108]. The low level of inhibition observed in vitro may be sufficient to gen-
erate a phenotype in vivo. Alternatively, ICP47 may block in vivo CD8+ T cell responses by ad-
ditional mechanisms. In vivo studies on all other human herpesviruses depend on humanized
mouse models. The identification of functional orthologs of, for example, US6 and BNLF2a in
the genomes of Old World primate-infecting herpesviruses offers new opportunities to evalu-
ate their contribution to replication and spread of the viruses in vivo. RhCMV, which encodes
functional homologs of HCMV US2, US3, US6 and US11 [109], has been used to study the role
of these immune evasion proteins in vivo [110]. RhCMV is known to be able to reinfect or su-
perinfect its host, despite the presence of high levels of neutralizing antibodies and RhCMV-
specific CD4+ and CD8+ T cells. However, rhesus macaques could not be superinfected by a
RhCMV strain in which the genetic region encoding the US2, US3, US6, and US11 homologs
was deleted. In contrast, the presence of these genes was not required for persistent infection of
RhCMV-naïve hosts or for superinfection of macaques transiently depleted of CD8+ T cells.
These studies indicate that impairment of MHC I presentation is critical for evading CD8+ T
cell responses during superinfection by RhCMV, but not during primary infection [110].
The recent identification of the first viral TAP inhibitor outside the family Herpesviridae
highlights the importance of targeting TAP function as a general viral immunoevasive strategy.
Poxviruses, like herpesviruses, are known for their elaborate strategies aimed at evading the
PLOS Pathogens | DOI:10.1371/journal.ppat.1004743 April 16, 2015 11 / 19
immune system. Cowpox virus (CPXV) is the first non-herpesvirus that has been found to en-
code a TAP inhibitor. This protein, CPXV012, is an ER-resident type II transmembrane pro-
tein of 69 amino acid residues that inhibits TAP through its ER-luminal domain by interfering
with ATP binding to the NBDs of TAP [111–113]. A recent analysis of this gene in a range of
CPXV strains has provided interesting clues as to the possible origin of the TAP-inhibiting ca-
pacity of CPXV012. It appears to have originated from a frameshifting deletion from a longer
protein that possesses an extended ER-luminal region containing a C-type lectin-like domain
[113,114]. The longer protein does not block TAP. The majority of the recently isolated clinical
strains encode the shorter, TAP-inhibiting protein [113].
The identification of TAP inhibitors in herpesviruses and poxviruses suggests that DNA vi-
ruses in particular benefit from interference with TAP function as a means to evade CD8+ T
cell responses. The absence of such evasion mechanisms in RNA viruses may in part be ex-
plained by the high mutation rate of RNA virus genomes, which allows for CD8+ T cell evasion
by antigenic variation [115,116]. The generally lower mutation rate of DNA viruses may re-
quire alternative immune evasion mechanisms, including TAP inhibition. The relatively large
genomes of herpes- and poxviruses have the capacity to accommodate dedicated immune eva-
sion proteins that counteract the host immune response.
Apart from TAP, MHC I itself is also targeted directly by a wide range of viral proteins en-
coded by herpesviruses and poxviruses. Among the alphaherpesviruses, ORF66 of VZV binds
to and accumulates MHC I in the Golgi compartment [117,118]. Several betaherpesviruses ex-
press proteins that induce degradation of MHC I via various pathways. US2, US10, and US11
of HCMV target MHC I for degradation via the ubiquitin-proteasome pathway [27–29].
MCMV-encoded gp48 and U21 of HHV-6 and HHV-7 mediate degradation of MHC I via the
endolysosomal route [30,119,120]. The m152 protein of MCMV retains MHC I in intracellular
compartments [35]. Rhesus CMV protein rh178 inhibits MHC I heavy chain expression by
preventing its co-translational insertion into the ER membrane [121]. Also members of the
gammaherpesvirus subfamily induce MHC I degradation using a variety of strategies. EBV-en-
coded BILF1 reroutes MHC I and targets it for lysosomal degradation [36,122]. MHV-68-en-
coded mK3 targets MHC I for proteasomal degradation [123], whereas kK3 and kk5 of KSHV
degrade MHC I through the endolysosomal pathway [38].
In addition to herperviruses, poxviruses and adenoviruses also encode gene products that
target MHC I directly. CPXV203 of cowpox virus and E3-19K of adenovirus both cause reten-
tion of MHC I in the ER [124–126].
The reduced overall MHC I surface expression induced by viral inhibitors makes cells more
vulnerable for NK cell recognition. NK cells sense the lack of MHC I on target cells; this may
result in a response depending on additional activation and inhibitory signals (reviewed by
[127]). Herpes- and poxviruses use a variety of gene products to counteract NK cell responses.
HCMV has been especially well studied for its ability to evade NK cell-mediated cytotoxicity
(reviewed in [128]), but other herpesviruses and poxviruses also encode gene products to coun-
teract NK cell-mediated cytotoxicity [129–131].
In conclusion, four classes of herpesvirus-encoded TAP inhibitors have been identified so
far. These appear to be unrelated and to have been acquired independently and relatively re-
cently during evolution, providing a powerful illustration of functional convergent evolution.
In addition, poxvirus CPXV012 has been shown to code for yet another type of TAP inhibitor.
Where in vitro and in vivo studies have been possible, they have demonstrated the significance
of TAP inhibitors in the evasion of CTL recognition and replication of the virus in the face of
potent immune responses. In addition to inhibition of TAP, MHC I function is inhibited by a
large repertoire of unrelated viral gene products directly targeting MHC I, representing yet an-
other example of functional convergent evolution. The acquisition of a wide range of unrelated
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proteins that interfere with MHC I-restricted antigen presentation highlights the importance
of CTLs in antiviral immunity.
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